R-SCT® (Rhenium Skin Cancer Therapy) for the treatment of light non-melanoma skin cancer uses radioactive Rhenium 188. For the majority of the patients (89 %) theepidermal radioisotope therapy is a single-session treatment depending on the depth of the lesion. R-SCT® is an effective, personalized and non-invasive treatment, independent of tumor size, severity and localization. Providing a fast, painless, single treatment with no side effects and aes¬thetic results. Meeting patient needs and bringing back quality of life. DSD Pharma is the first and only distributor to supply the innovative R-SCT to nuclear medicine departments in Austria.
Spectrum Dermatologie 13.05.2022 (German)
Aerzte Krone 06.05.2022 (German)
ORF 11.03.2022
